Core Insights - GE HealthCare reported revenues of $20.6 billion for fiscal year 2025, driven by strong imaging demand, and expects earnings per share for FY26 to be between $4.95 and $5.15, surpassing analysts' estimates of $4.92 [1][2] Financial Performance - The company's FY25 revenues represent a growth margin of 4.8% compared to FY24 revenues of $19.7 billion, primarily due to robust performance in imaging and advanced visualization solutions [2] - Imaging revenue reached $9.25 billion in FY25, a 4.4% increase from $8.86 billion in FY24, while advanced visualization solutions generated $5.35 billion, reflecting a 4.3% growth from $5.13 billion in FY24 [3] - Patient care solutions revenues declined by 1.2% to approximately $3 billion, down from $3.12 billion in FY24 [3] Growth Verticals - The pharmaceutical diagnostics vertical showed the most significant growth, with revenues of $2.9 billion, marking a 15.6% increase from $2.5 billion in FY24 [4] - In Q4 2025, total revenues were $5.7 billion, with imaging growing by 6.6% to $2.55 billion, advanced visualization solutions increasing by 5.9% to $1.52 billion, and pharmaceutical diagnostics rising by 22.3% to $790 million [5] Strategic Initiatives - CEO Peter Arduini emphasized the company's focus on precision care, growth acceleration, and business optimization, highlighting successful execution of its strategy [6] - The company is pursuing a disciplined approach to mergers and acquisitions to enhance its portfolio and is committed to organic investment and product development [6] - GE HealthCare announced an agreement to acquire Intelerad, a medical imaging software provider, for $2.3 billion, aiming to expand its range of cloud-enabled products by 2028 [7]